TH155333A - Composed elements and Method of use Sodium-Glucose Co inhibitors Transporters (cotransporters) 1 and 2 - Google Patents
Composed elements and Method of use Sodium-Glucose Co inhibitors Transporters (cotransporters) 1 and 2Info
- Publication number
- TH155333A TH155333A TH1301003598A TH1301003598A TH155333A TH 155333 A TH155333 A TH 155333A TH 1301003598 A TH1301003598 A TH 1301003598A TH 1301003598 A TH1301003598 A TH 1301003598A TH 155333 A TH155333 A TH 155333A
- Authority
- TH
- Thailand
- Prior art keywords
- cardiovascular
- type
- diabetes
- health
- disclosed
- Prior art date
Links
- YKXCWZVUWWQSAV-BTVCFUMJSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O YKXCWZVUWWQSAV-BTVCFUMJSA-N 0.000 title 1
- 102000037121 Cotransporter Human genes 0.000 title 1
- 108020003264 Cotransporter Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000000271 cardiovascular Effects 0.000 claims abstract 6
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 4
- 230000002503 metabolic Effects 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 3
- 201000010099 disease Diseases 0.000 claims abstract 2
- 239000002552 dosage form Substances 0.000 claims abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- FYGDTMLNYKFZSV-MRCIVHHJSA-N Dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
Abstract
DC60 (23/09/56) ได้เปิดเผยถึงรูปเเบบทางเภสัชกรรมของปริมาณขนาดยาที่ให้ทีมีประโยชน์สำหรับการปรับปรุงโรค หลอดเลือดหัวใจ(cardiovascular) เเละ/ หรือสุขภาพทางเมตาโบลิซึ่ม(metabolic health)ของผู้ป่วย โดยเฉพาะคนเหล่านั้นที่ทนทุกข์ทรมานจากโรคเบาหวาน (diabetes) ชนิดที่ 2 ตลอดจนวิธีการของการ ผลิตของมัน ได้เปิดเผยถึงรูปเเบบทางเภสัชกรรมของปริมาณขนาดยาที่ให้ที่มีประโยชน์ สำหรับการปรับปรุงโรคหลอดเลือดหัวใจ(cardiovascular)เเละ/หรือสุขภาพทางเมตรชตาโบลิซิ่ม (metablic health)ของผู้ป่วยโดยเฉพาะคนเหล่านั้นที่ทนทุกข์ทรมานจากโรคเบาหวาน(diabctes) ชนิดที่ 2 ตลอดจนวิธีการของการผลิตของมัน สิทธิบัตรยา DC60 (23/09/56) has disclosed the pharmaceutical form of the dosage form that is useful for disease improvement. Cardiovascular (cardiovascular) and / or metabolic health (metabolic health) of the patient In particular, those people suffering from type 2 diabetes and their methods of manufacture have disclosed the pharmaceutical form of a useful dose given. For improving cardiovascular and / or metablic health of patients, especially those suffering from type 2 diabetes (diabctes) as well as interventions. The production of its patent medicine
Claims (1)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TH155333A true TH155333A (en) | 2016-08-11 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201491060A1 (en) | NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE | |
| MX360554B (en) | Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2. | |
| BR112015018168A2 (en) | soft rock inhibitors | |
| EA201001577A1 (en) | DPP-4 INHIBITOR IN A COMBINATION WITH AN ADDITIONAL ANTI-DIABETIC AGENT, TABLETS INCLUDING THE SPECIFIED COMPOSITIONS, THEIR APPLICATION AND METHOD OF THEIR PRODUCTION | |
| MX357780B (en) | Polycyclic derivatives, preparation method and medical uses thereof. | |
| MX342423B (en) | 6 -benzylphenyl- 2 - sulfurterahydropyran-3, 4, 5 -triol derivatives as inhibitors of sodium -glucose cotrans porters 1 and 2 for use in diabetic patients. | |
| EA201690069A1 (en) | THE USE OF HIGH DOSE PRIDOPIDINE FOR THE TREATMENT OF THE HANTINGTON'S DISEASE | |
| EA201270221A1 (en) | TREATMENT OF CROWN DISEASE WITH LACQUINIMODE | |
| EA201391651A1 (en) | SO-CRYSTALS OF L-PROLINE AND LEMONIC ACID (2S, 3R, 4R, 5S, 6R) -2- (3 - ((5- (4-FTORPHENYL) TIOPHEN-2-IL) METHYL) -4-METHILPHENYL) -6- ( HYDROXYMETHYL) TETRAHYDRO-2H-PIRAN-3,4,5-TRIOL | |
| UA107578C2 (en) | COMBINED DIABETES THERAPY | |
| NZ714684A (en) | Stable oral solutions for combined api | |
| TN2009000275A1 (en) | Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome | |
| EA201890532A1 (en) | NEW ANNELED BENZAMIDES | |
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
| PL2244703T3 (en) | Pharmaceuticals and the production and use thereof in the treatment of painful neuropathies | |
| EA201691299A1 (en) | APPLICATION OF LACHINIMODA TO SLOW DOWN THE PROGRESSION OF HANTINGTON'S DISEASE | |
| TH155333A (en) | Composed elements and Method of use Sodium-Glucose Co inhibitors Transporters (cotransporters) 1 and 2 | |
| WO2014195900A3 (en) | Oral pharmaceutical compositions for use in dyslipidemias | |
| RU2012147055A (en) | METHOD FOR PREVENTION OF INTRAHEPENAL PORTAL HYPERTENSION IN PATIENTS AFTER LIVER RESECTION | |
| RU2012115039A (en) | METHOD FOR TREATING CHRONIC ENDOMETRITIS | |
| EA201200799A1 (en) | HEPATATROPETECTED MEDICINE | |
| TH1701001130A (en) | The use of constituents incorporating a dual PI3K delta-gamma kinase inhibitor. And corticosteroids | |
| TH156289A (en) | (R) - Nifuratel, its use for the treatment of infection. And synthesis (R) and (S) - nifuratel. | |
| TH161923A (en) | Solid units with high phosphenadine content and processes for Preparation of such things | |
| TH147179A (en) | The process for the preparation of a pharmaceutical component containing perephenidone in the form of long-acting tablets. And the use of that in their mitigation Chronic renal failure, breast fibrosis, and human hepatic fibrosis. |